



## Review

## Involvement of Mediator complex in malignancy



Concetta Schiano <sup>a,1</sup>, Amelia Casamassimi <sup>b,\*</sup>, Monica Rienzo <sup>b</sup>, Filomena de Nigris <sup>b</sup>,  
Linda Sommese <sup>c</sup>, Claudio Napoli <sup>a,b,c</sup>

<sup>a</sup> Institute of Diagnostic and Nuclear Development (SDN), IRCCS, Via E. Gianturco 113, 80143 Naples, Italy

<sup>b</sup> Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Via L. De Crecchio 7, 80138 Naples, Italy

<sup>c</sup> U.O.C. Immunohematology, Transfusion Medicine and Transplant Immunology [SIMT], Regional Reference Laboratory of Transplant Immunology [LIT], Azienda Universitaria Policlinico (AOU), 1st School of Medicine, Second University of Naples, Piazza Miraglia 2, 80138 Naples, Italy

## ARTICLE INFO

## Article history:

Received 19 July 2013

Received in revised form 28 November 2013

Accepted 9 December 2013

Available online 14 December 2013

## Keywords:

Mediator complex

Cancer

Transcription

Tumorigenesis

Biomarkers

## ABSTRACT

Mediator complex (MED) is an evolutionarily conserved multiprotein, fundamental for growth and survival of all cells. In eukaryotes, the mRNA transcription is dependent on RNA polymerase II that is associated to various molecules like general transcription factors, MED subunits and chromatin regulators. To date, transcriptional machinery dysfunction has been shown to elicit broad effects on cell proliferation, development, differentiation, and pathologic disease induction, including cancer. Indeed, in malignant cells, the improper activation of specific genes is usually ascribed to aberrant transcription machinery. Here, we focus our attention on the correlation of MED subunits with carcinogenesis. To date, many subunits are mutated or display altered expression in human cancers. Particularly, the role of MED1, MED28, MED12, CDK8 and Cyclin C in cancer is well documented, although several studies have recently reported a possible association of other subunits with malignancy. Definitely, a major comprehension of the involvement of the whole complex in cancer may lead to the identification of MED subunits as novel diagnostic/prognostic tumour markers to be used in combination with imaging technique in clinical oncology, and to develop novel anti-cancer targets for molecular-targeted therapy.

© 2013 Published by Elsevier B.V.

## Contents

1.	Introduction	67
2.	Mediator complex in malignancy	68
2.1.	MED1	72
2.1.1.	Breast cancer	72
2.1.2.	Prostate cancer	73
2.1.3.	Lung cancer	73
2.1.4.	Melanoma	73
2.2.	MED2	73
2.2.1.	Pancreatic cancer	73
2.3.	MED4	74
2.3.1.	Cervical cancer	74
2.3.2.	Retinoblastoma	74
2.4.	MED5	74
2.4.1.	Breast cancer	74
2.4.2.	Prostate cancer	74
2.5.	MED12	74
2.5.1.	Breast cancer	74
2.5.2.	Prostate cancer	74
2.5.3.	Uterine sarcomas	74
2.5.4.	Colon cancer	74
2.5.5.	Lung cancer	75

\* Corresponding author at: Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Via L. De Crecchio, 80138 Naples, Italy. Tel.: +39 0815667567; fax: +39 081450169.

E-mail address: [amelia.casamassimi@unina2.it](mailto:amelia.casamassimi@unina2.it) (A. Casamassimi).

<sup>1</sup> These two authors contributed equally to this study.

2.6.	MED13	75
2.6.1.	Brain cancer	75
2.6.2.	Breast cancer	75
2.7.	MED13L	75
2.7.1.	Retinoblastoma	75
2.8.	MED14	75
2.8.1.	Breast cancer	75
2.8.2.	Prostate cancer	76
2.9.	MED15	76
2.9.1.	Breast cancer	76
2.9.2.	Prostate cancer	76
2.10.	MED17	76
2.10.1.	Prostate cancer	76
2.11.	MED19	76
2.11.1.	Bladder cancer	76
2.11.2.	Breast cancer	76
2.11.3.	Colorectal cancer	76
2.11.4.	Gastric cancer	76
2.11.5.	Hepatocellular carcinoma	76
2.11.6.	Lung cancer	76
2.11.7.	Osteosarcoma	77
2.11.8.	Ovarian cancer	77
2.11.9.	Pancreatic cancer	77
2.11.10.	Prostate cancer	77
2.11.11.	Tongue carcinoma	77
2.12.	MED23	77
2.12.1.	Breast cancer	77
2.12.2.	Gastric cancer	77
2.12.3.	Lung cancer	77
2.12.4.	Melanoma	77
2.12.5.	Pheochromocytoma	78
2.13.	MED28	78
2.13.1.	Breast cancer	78
2.13.2.	Prostate cancer	78
2.13.3.	Colon cancer	78
2.14.	MED30	78
2.14.1.	Breast cancer	78
2.15.	CDK19	78
2.15.1.	Osteosarcoma	78
2.15.2.	Myeloma	78
2.16.	CDK8 (kinase or module)	78
2.16.1.	Colon cancer	79
2.16.2.	Melanoma	79
2.16.3.	Other tumours	79
2.17.	Cyclin C	79
2.17.1.	Colon cancer	79
2.17.2.	Gastric cancer	79
2.17.3.	Leukaemia	79
2.17.4.	Hepatocellular carcinoma	79
2.17.5.	Osteosarcoma	80
3.	Conclusions and future perspectives	80
	Conflict of interest statement	80
	References	81

## 1. Introduction

Transcriptional regulation is one of the most important steps in the control of cell identity, growth, differentiation and development. Many signalling pathways, which control these processes, ultimately target the core transcription machinery. For protein coding genes, this apparatus consists of RNA polymerase II (Pol II) and the general transcription factors (TFs) TFIIA, TFIIB, TFIID, TFIIE, TFIIIF and TFIIH that contact Mediator complex (MED). MED is the essential coactivator/activator complex acting as a bridge between transcription factors bound at the upstream regulatory elements and the transcription machinery. Crucially, the pre-initiation complex (PIC) consists of MED, Pol II and TFs [1], with MED as a central scaffold within the PIC and regulator of Pol II activity [2–4]. It strongly interacts with Pol II, changes its conformation and

influences the transcription initiation process as well as other transcription steps, although the whole involved molecular mechanisms have not yet fully elucidated [5,6]. At present, mammalian MED is composed of at least 31 subunits that are arranged in four structurally distinct modules, head, middle and tail modules representing the main complex core, and kinase module (CDK module), variably associated with the core (Fig. 1) [1,3,7–10]. Structural and biochemical studies have recently revealed the existence of further sub-modules [8,11]. The head and middle modules, containing CDK19 kinase, are known to interact directly with Pol II, whereas the tail module interacts with gene-specific regulatory proteins [2,4,7,8]. In particular, the head module interacts with the Pol II subunit Rpb3 through the MED17 subunit [12,13] whereas MED11 and MED22, other two important head subunits, interact with the TFIIH subunit Rad3 [14]. Finally, crystal structure

Download English Version:

<https://daneshyari.com/en/article/10895615>

Download Persian Version:

<https://daneshyari.com/article/10895615>

[Daneshyari.com](https://daneshyari.com)